Eclipsebio completed the acquisition of Terrain Bio to accelerate its end‑to‑end RNA therapeutic platform by adding Terrain’s machine‑learning RNA analytics and design capabilities. Eclipsebio said the deal integrates Terrain’s AI‑driven analytics with its sequencing‑first validation workflows to support iterative RNA design, high‑resolution impurity profiling, and quality‑by‑design for RNA drug manufacturing. The acquisition brings together AI design and deep sequencing validation under one commercial roof, shortening the feedback loop between molecule design and manufacturability. For RNA developers, the combined platform aims to reduce failure modes during scale‑up and speed candidate selection prior to clinical batches. Clarification: 'Quality‑by‑design' refers to proactively designing manufacturing processes and analytics so that product quality is built into each step rather than tested only at the end.